MX2022012855A - Virus adenoasociado con cápside modificada geneticamente. - Google Patents

Virus adenoasociado con cápside modificada geneticamente.

Info

Publication number
MX2022012855A
MX2022012855A MX2022012855A MX2022012855A MX2022012855A MX 2022012855 A MX2022012855 A MX 2022012855A MX 2022012855 A MX2022012855 A MX 2022012855A MX 2022012855 A MX2022012855 A MX 2022012855A MX 2022012855 A MX2022012855 A MX 2022012855A
Authority
MX
Mexico
Prior art keywords
capsid
associated virus
engineered
adeno
virions
Prior art date
Application number
MX2022012855A
Other languages
English (en)
Inventor
Christopher A Reid
Ze Cheng
Original Assignee
Tenaya Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tenaya Therapeutics Inc filed Critical Tenaya Therapeutics Inc
Publication of MX2022012855A publication Critical patent/MX2022012855A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona viriones de virus adenoasociados recombinantes (rAAV) con una proteína de la cápside modificada genéticamente. En particular, la descripción proporciona viriones de AAV9 con cápside de AAV9 modificada genéticamente, cápside quimérica de AAV5/9 o cápside combinatoria que logra una mayor eficiencia de transducción en células cardíacas, una mayor selectividad de tipo celular y/u otras propiedades convenientes.
MX2022012855A 2020-04-20 2021-04-19 Virus adenoasociado con cápside modificada geneticamente. MX2022012855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063012703P 2020-04-20 2020-04-20
PCT/US2021/027979 WO2021216456A2 (en) 2020-04-20 2021-04-19 Adeno-associated virus with engineered capsid

Publications (1)

Publication Number Publication Date
MX2022012855A true MX2022012855A (es) 2023-01-04

Family

ID=78269888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012855A MX2022012855A (es) 2020-04-20 2021-04-19 Virus adenoasociado con cápside modificada geneticamente.

Country Status (12)

Country Link
US (1) US20230220014A1 (es)
EP (1) EP4139443A2 (es)
JP (1) JP2023522106A (es)
KR (1) KR20230004719A (es)
CN (1) CN115997011A (es)
AU (1) AU2021259422A1 (es)
BR (1) BR112022021134A2 (es)
CA (1) CA3180202A1 (es)
CO (1) CO2022016592A2 (es)
IL (1) IL297391A (es)
MX (1) MX2022012855A (es)
WO (1) WO2021216456A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096734A (zh) 2020-05-13 2023-05-09 沃雅戈治疗公司 Aav衣壳的向性的重定向
KR20230043869A (ko) 2020-08-07 2023-03-31 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
WO2023091934A1 (en) * 2021-11-16 2023-05-25 California Institute Of Technology Adeno-associated virus compositions having preferred heart and skeletal muscle enrichment
TW202404993A (zh) 2022-04-11 2024-02-01 美商特納亞治療股份有限公司 具經工程化蛋白殼之腺相關病毒
WO2024038345A1 (en) * 2022-08-19 2024-02-22 Lubrizol Advanced Materials, Inc. Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
WO2024064863A2 (en) * 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164757A1 (en) * 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US20210371471A1 (en) * 2018-04-03 2021-12-02 Stridebio, Inc. Antibody-evading virus vectors

Also Published As

Publication number Publication date
BR112022021134A2 (pt) 2023-02-14
WO2021216456A3 (en) 2021-12-02
US20230220014A1 (en) 2023-07-13
CN115997011A (zh) 2023-04-21
AU2021259422A1 (en) 2022-12-08
WO2021216456A2 (en) 2021-10-28
IL297391A (en) 2022-12-01
KR20230004719A (ko) 2023-01-06
CA3180202A1 (en) 2021-10-28
CO2022016592A2 (es) 2022-11-29
EP4139443A2 (en) 2023-03-01
JP2023522106A (ja) 2023-05-26

Similar Documents

Publication Publication Date Title
MX2022012855A (es) Virus adenoasociado con cápside modificada geneticamente.
WO2018160582A8 (en) Adeno-associated virus (aav) clade f vector and uses therefor
MX2021013268A (es) Nuevas capsides de aav y composiciones que las contienen.
NZ763018A (en) Adeno-associated virus variant capsids and methods of use thereof
MX2019010910A (es) Viriones de virus adenoasociados con capsides variantes y metodos para su uso.
MX2020000663A (es) Produccion mejorada de capside de virus adeno-asociado (aav) en celulas de insectos.
PH12020551938A1 (en) Liver targeting adeno-associated viral vectors
MX2016011585A (es) Vectores aav mejorados adicionales producidos en celulas de insecto.
MX2020008932A (es) Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
EA201792236A1 (ru) Получение увеличенных в размере векторов на основе аденоассоциированного вируса
EP2311966A3 (en) Improved AAV vectors produced in insect cells
EA202192501A1 (ru) Рекомбинантные аденоассоциированные вирусные векторы
IL196091A (en) A nucleotide sequence with an engineered start codon for 78rep – aav translation and their use to generate aav in insect cells, and cells containing them
ES2629380T3 (es) Viriones de AAV con inmunorreactividad reducida y usos de los mismos
WO2022076750A3 (en) Recombinant adeno-associated viruses for cns or muscle delivery
MX2021012311A (es) Variantes de capsides de aav para liberacion intravitrea.
MX2023001863A (es) Nuevas cápsides de aav y composiciones que las contienen.
MX2022002184A (es) Proteina vp1 modificada aislada de la capside del virus adeno-asociado de serotipo 5 (aav5), capside y vector basado en la misma.
MX2023005113A (es) Cápsides de aav y composiciones que las contienen.
MX2022013819A (es) Capsides de virus adeno-asociado 5 modificado y usos del mismo.
MX2023000994A (es) Genoterapia con csrp3 (proteina 3 rica en cisteina y glicina).
MX2023001419A (es) Vector viral adenoasociado para la expresion de glut1 y usos de este.
WO2023225007A3 (en) Engineered viral vectors with enhanced packaging capacity and methods of using the same
FI3177313T3 (fi) Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi
MX2023003807A (es) Virus adenoasociados recombinantes para administracion en el snc o el musculo.